

# COVID-19 Impact on Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/CCFF2C372B6CEN.html>

Date: September 2020

Pages: 133

Price: US\$ 3,900.00 (Single User License)

ID: CCFF2C372B6CEN

## Abstracts

This report focuses on the global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The key players covered in this study

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

Eisai

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

Genzyme Corporation

GW Pharmaceuticals Plc

ImmunoCellular Therapeutics, Ltd.

Market segment by Type, the product can be split into

AU-105

Axitinib

AXL-1717

AZD-7451

Others

Market segment by Application, split into

Hospital

Clinic

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Recurrent Glioblastoma Multiforme Treatment status, future forecast, growth opportunity, key market and key players.

To present the Recurrent Glioblastoma Multiforme Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme Treatment are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue

1.4 Market Analysis by Type

1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 AU-105

1.4.3 Axitinib

1.4.4 AXL-1717

1.4.5 AZD-7451

1.4.6 Others

1.5 Market by Application

1.5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19): Recurrent Glioblastoma Multiforme Treatment Industry Impact

1.6.1 How the Covid-19 is Affecting the Recurrent Glioblastoma Multiforme Treatment Industry

1.6.1.1 Recurrent Glioblastoma Multiforme Treatment Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Recurrent Glioblastoma Multiforme Treatment Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Recurrent Glioblastoma Multiforme Treatment Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

## **2 GLOBAL GROWTH TRENDS BY REGIONS**

- 2.1 Recurrent Glioblastoma Multiforme Treatment Market Perspective (2015-2026)
- 2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Regions
  - 2.2.1 Recurrent Glioblastoma Multiforme Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  - 2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Share by Regions (2015-2020)
  - 2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
  - 2.3.1 Market Top Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Challenges
  - 2.3.4 Porter's Five Forces Analysis
  - 2.3.5 Recurrent Glioblastoma Multiforme Treatment Market Growth Strategy
  - 2.3.6 Primary Interviews with Key Recurrent Glioblastoma Multiforme Treatment Players (Opinion Leaders)

## **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

- 3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Market Size
  - 3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2015-2020)
  - 3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2015-2020)
  - 3.1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
  - 3.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
  - 3.2.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2019
- 3.3 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
- 3.4 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
- 3.5 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
- 3.6 Mergers & Acquisitions, Expansion Plans

## **4 BREAKDOWN DATA BY TYPE (2015-2026)**

4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2015-2020)

4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2021-2026)

## **5 RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)**

5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2021-2026)

## **6 NORTH AMERICA**

6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

6.2 Recurrent Glioblastoma Multiforme Treatment Key Players in North America (2019-2020)

6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **7 EUROPE**

7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

7.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Europe (2019-2020)

7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **8 CHINA**

8.1 China Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

8.2 Recurrent Glioblastoma Multiforme Treatment Key Players in China (2019-2020)

8.3 China Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

8.4 China Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **9 JAPAN**

9.1 Japan Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

9.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Japan (2019-2020)

9.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

9.4 Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

10.1 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

10.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

10.4 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **11 INDIA**

11.1 India Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)

11.2 Recurrent Glioblastoma Multiforme Treatment Key Players in India (2019-2020)

11.3 India Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

11.4 India Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

12.1 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size (2015-2020)



12.2 Recurrent Glioblastoma Multiforme Treatment Key Players in Central & South America (2019-2020)

12.3 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)

12.4 Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

13.1 Boehringer Ingelheim GmbH

13.1.1 Boehringer Ingelheim GmbH Company Details

13.1.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue

13.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction

13.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

13.1.5 Boehringer Ingelheim GmbH Recent Development

13.2 Boston Biomedical, Inc.

13.2.1 Boston Biomedical, Inc. Company Details

13.2.2 Boston Biomedical, Inc. Business Overview and Its Total Revenue

13.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction

13.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

13.2.5 Boston Biomedical, Inc. Recent Development

13.3 Bristol-Myers Squibb Company

13.3.1 Bristol-Myers Squibb Company Company Details

13.3.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue

13.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction

13.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

13.3.5 Bristol-Myers Squibb Company Recent Development

13.4 Cantex Pharmaceuticals, Inc.

13.4.1 Cantex Pharmaceuticals, Inc. Company Details

13.4.2 Cantex Pharmaceuticals, Inc. Business Overview and Its Total Revenue

13.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction

13.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme

## Treatment Business (2015-2020)

### 13.4.5 Cantex Pharmaceuticals, Inc. Recent Development

## 13.5 Cavion LLC

### 13.5.1 Cavion LLC Company Details

### 13.5.2 Cavion LLC Business Overview and Its Total Revenue

### 13.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction

### 13.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment

## Business (2015-2020)

### 13.5.5 Cavion LLC Recent Development

## 13.6 Celldex Therapeutics, Inc.

### 13.6.1 Celldex Therapeutics, Inc. Company Details

### 13.6.2 Celldex Therapeutics, Inc. Business Overview and Its Total Revenue

### 13.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction

### 13.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

### 13.6.5 Celldex Therapeutics, Inc. Recent Development

## 13.7 Coherus BioSciences, Inc.

### 13.7.1 Coherus BioSciences, Inc. Company Details

### 13.7.2 Coherus BioSciences, Inc. Business Overview and Its Total Revenue

### 13.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction

### 13.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

### 13.7.5 Coherus BioSciences, Inc. Recent Development

## 13.8 Cortice Biosciences, Inc.

### 13.8.1 Cortice Biosciences, Inc. Company Details

### 13.8.2 Cortice Biosciences, Inc. Business Overview and Its Total Revenue

### 13.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction

### 13.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

### 13.8.5 Cortice Biosciences, Inc. Recent Development

## 13.9 Eisai

### 13.9.1 Eisai Company Details

### 13.9.2 Eisai Business Overview and Its Total Revenue

### 13.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction

### 13.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

- 13.9.5 Eisai Recent Development
- 13.10 Eli Lilly and Company
  - 13.10.1 Eli Lilly and Company Company Details
  - 13.10.2 Eli Lilly and Company Business Overview and Its Total Revenue
  - 13.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
  - 13.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  - 13.10.5 Eli Lilly and Company Recent Development
- 13.11 EnGenelC Ltd
  - 10.11.1 EnGenelC Ltd Company Details
  - 10.11.2 EnGenelC Ltd Business Overview and Its Total Revenue
  - 10.11.3 EnGenelC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
  - 10.11.4 EnGenelC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  - 10.11.5 EnGenelC Ltd Recent Development
- 13.12 ERC Belgium SA
  - 10.12.1 ERC Belgium SA Company Details
  - 10.12.2 ERC Belgium SA Business Overview and Its Total Revenue
  - 10.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
  - 10.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  - 10.12.5 ERC Belgium SA Recent Development
- 13.13 GenSpera, Inc.
  - 10.13.1 GenSpera, Inc. Company Details
  - 10.13.2 GenSpera, Inc. Business Overview and Its Total Revenue
  - 10.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
  - 10.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  - 10.13.5 GenSpera, Inc. Recent Development
- 13.14 Genzyme Corporation
  - 10.14.1 Genzyme Corporation Company Details
  - 10.14.2 Genzyme Corporation Business Overview and Its Total Revenue
  - 10.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
  - 10.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)
  - 10.14.5 Genzyme Corporation Recent Development
- 13.15 GW Pharmaceuticals Plc

10.15.1 GW Pharmaceuticals Plc Company Details

10.15.2 GW Pharmaceuticals Plc Business Overview and Its Total Revenue

10.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment

Introduction

10.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

10.15.5 GW Pharmaceuticals Plc Recent Development

13.16 ImmunoCellular Therapeutics, Ltd.

10.16.1 ImmunoCellular Therapeutics, Ltd. Company Details

10.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview and Its Total Revenue

10.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme

Treatment Introduction

10.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

10.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

## List Of Tables

### LIST OF TABLES

- Table 1. Recurrent Glioblastoma Multiforme Treatment Key Market Segments
- Table 2. Key Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
- Table 3. Ranking of Global Top Recurrent Glioblastoma Multiforme Treatment Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of AU-105
- Table 6. Key Players of Axitinib
- Table 7. Key Players of AXL-1717
- Table 8. Key Players of AZD-7451
- Table 9. Key Players of Others
- Table 10. COVID-19 Impact Global Market: (Four Recurrent Glioblastoma Multiforme Treatment Market Size Forecast Scenarios)
- Table 11. Opportunities and Trends for Recurrent Glioblastoma Multiforme Treatment Players in the COVID-19 Landscape
- Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 13. Key Regions/Countries Measures against Covid-19 Impact
- Table 14. Proposal for Recurrent Glioblastoma Multiforme Treatment Players to Combat Covid-19 Impact
- Table 15. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 16. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 17. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Regions (2015-2020) (US\$ Million)
- Table 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2015-2020)
- Table 19. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 20. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2021-2026)
- Table 21. Market Top Trends
- Table 22. Key Drivers: Impact Analysis
- Table 23. Key Challenges

Table 24. Recurrent Glioblastoma Multiforme Treatment Market Growth Strategy

Table 25. Main Points Interviewed from Key Recurrent Glioblastoma Multiforme Treatment Players

Table 26. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2015-2020) (Million US\$)

Table 27. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players (2015-2020)

Table 28. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2019)

Table 29. Global Recurrent Glioblastoma Multiforme Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service

Table 32. Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 35. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Type (2015-2020)

Table 36. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2021-2026)

Table 37. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2015-2020)

Table 38. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 39. Global Recurrent Glioblastoma Multiforme Treatment Market Size Share by Application (2021-2026)

Table 40. North America Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 41. North America Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 42. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 43. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 44. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)



Table 45. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 46. Europe Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 47. Europe Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 48. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 49. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 50. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 52. China Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 54. China Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 55. China Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 56. China Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 57. China Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 58. Japan Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 60. Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 62. Japan Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Recurrent Glioblastoma Multiforme Treatment

Revenue (2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 66. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 68. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 70. India Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 71. India Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 72. India Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 73. India Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 74. India Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 75. India Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Recurrent Glioblastoma Multiforme Treatment Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Recurrent Glioblastoma Multiforme Treatment Market Share (2019-2020)

Table 78. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2015-2020) (Million US\$)

Table 79. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2015-2020)

Table 80. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2015-2020) (Million US\$)

Table 81. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2015-2020)

Table 82. Boehringer Ingelheim GmbH Company Details

Table 83. Boehringer Ingelheim GmbH Business Overview

Table 84. Boehringer Ingelheim GmbH Product

Table 85. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme



Treatment Business (2015-2020) (Million US\$)

Table 86. Boehringer Ingelheim GmbH Recent Development

Table 87. Boston Biomedical, Inc. Company Details

Table 88. Boston Biomedical, Inc. Business Overview

Table 89. Boston Biomedical, Inc. Product

Table 90. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme

Treatment Business (2015-2020) (Million US\$)

Table 91. Boston Biomedical, Inc. Recent Development

Table 92. Bristol-Myers Squibb Company Company Details

Table 93. Bristol-Myers Squibb Company Business Overview

Table 94. Bristol-Myers Squibb Company Product

Table 95. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma

Multiforme Treatment Business (2015-2020) (Million US\$)

Table 96. Bristol-Myers Squibb Company Recent Development

Table 97. Cantex Pharmaceuticals, Inc. Company Details

Table 98. Cantex Pharmaceuticals, Inc. Business Overview

Table 99. Cantex Pharmaceuticals, Inc. Product

Table 100. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma

Multiforme Treatment Business (2015-2020) (Million US\$)

Table 101. Cantex Pharmaceuticals, Inc. Recent Development

Table 102. Cavion LLC Company Details

Table 103. Cavion LLC Business Overview

Table 104. Cavion LLC Product

Table 105. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment

Business (2015-2020) (Million US\$)

Table 106. Cavion LLC Recent Development

Table 107. Celldex Therapeutics, Inc. Company Details

Table 108. Celldex Therapeutics, Inc. Business Overview

Table 109. Celldex Therapeutics, Inc. Product

Table 110. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme

Treatment Business (2015-2020) (Million US\$)

Table 111. Celldex Therapeutics, Inc. Recent Development

Table 112. Coherus BioSciences, Inc. Company Details

Table 113. Coherus BioSciences, Inc. Business Overview

Table 114. Coherus BioSciences, Inc. Product

Table 115. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme

Treatment Business (2015-2020) (Million US\$)

Table 116. Coherus BioSciences, Inc. Recent Development

Table 117. Cortice Biosciences, Inc. Business Overview

- Table 118. Cortice Biosciences, Inc. Product
- Table 119. Cortice Biosciences, Inc. Company Details
- Table 120. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 121. Cortice Biosciences, Inc. Recent Development
- Table 122. Eisai Company Details
- Table 123. Eisai Business Overview
- Table 124. Eisai Product
- Table 125. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 126. Eisai Recent Development
- Table 127. Eli Lilly and Company Company Details
- Table 128. Eli Lilly and Company Business Overview
- Table 129. Eli Lilly and Company Product
- Table 130. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 131. Eli Lilly and Company Recent Development
- Table 132. EnGeneIC Ltd Company Details
- Table 133. EnGeneIC Ltd Business Overview
- Table 134. EnGeneIC Ltd Product
- Table 135. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 136. EnGeneIC Ltd Recent Development
- Table 137. ERC Belgium SA Company Details
- Table 138. ERC Belgium SA Business Overview
- Table 139. ERC Belgium SA Product
- Table 140. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 141. ERC Belgium SA Recent Development
- Table 142. GenSpera, Inc. Company Details
- Table 143. GenSpera, Inc. Business Overview
- Table 144. GenSpera, Inc. Product
- Table 145. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020) (Million US\$)
- Table 146. GenSpera, Inc. Recent Development
- Table 147. Genzyme Corporation Company Details
- Table 148. Genzyme Corporation Business Overview
- Table 149. Genzyme Corporation Product
- Table 150. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme

Treatment Business (2015-2020) (Million US\$)

Table 151. Genzyme Corporation Recent Development

Table 152. GW Pharmaceuticals Plc Company Details

Table 153. GW Pharmaceuticals Plc Business Overview

Table 154. GW Pharmaceuticals Plc Product

Table 155. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme

Treatment Business (2015-2020) (Million US\$)

Table 156. GW Pharmaceuticals Plc Recent Development

Table 157. ImmunoCellular Therapeutics, Ltd. Company Details

Table 158. ImmunoCellular Therapeutics, Ltd. Business Overview

Table 159. ImmunoCellular Therapeutics, Ltd. Product

Table 160. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma

Multiforme Treatment Business (2015-2020) (Million US\$)

Table 161. ImmunoCellular Therapeutics, Ltd. Recent Development

Table 162. Research Programs/Design for This Report

Table 163. Key Data Information from Secondary Sources

Table 164. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type: 2020 VS 2026

Figure 2. AU-105 Features

Figure 3. Axitinib Features

Figure 4. AXL-1717 Features

Figure 5. AZD-7451 Features

Figure 6. Others Features

Figure 7. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Others Case Studies

Figure 11. Recurrent Glioblastoma Multiforme Treatment Report Years Considered

Figure 12. Global Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions: 2020 VS 2026

Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Regions (2021-2026)

Figure 15. Porter's Five Forces Analysis

Figure 16. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players in 2019

Figure 17. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2019)

Figure 18. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2019

Figure 19. North America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Europe Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. China Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Japan Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. India Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Central & South America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Boehringer Ingelheim GmbH Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Boehringer Ingelheim GmbH Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 28. Boston Biomedical, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Boston Biomedical, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 30. Bristol-Myers Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Bristol-Myers Squibb Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 32. Cantex Pharmaceuticals, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Cantex Pharmaceuticals, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 34. Cavion LLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Cavion LLC Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 36. Celldex Therapeutics, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Celldex Therapeutics, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 38. Coherus BioSciences, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Coherus BioSciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 40. Cortice Biosciences, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Cortice Biosciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 42. Eisai Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Eisai Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment

Business (2015-2020)

Figure 44. Eli Lilly and Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Eli Lilly and Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 46. EnGeneIC Ltd Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. EnGeneIC Ltd Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 48. ERC Belgium SA Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. ERC Belgium SA Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 50. GenSpera, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. GenSpera, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 52. Genzyme Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Genzyme Corporation Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 54. GW Pharmaceuticals Plc Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. GW Pharmaceuticals Plc Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 56. ImmunoCellular Therapeutics, Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. ImmunoCellular Therapeutics, Ltd. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2015-2020)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

## I would like to order

Product name: COVID-19 Impact on Global Recurrent Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/CCFF2C372B6CEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCFF2C372B6CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



